Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TriAd
- Development stage
- Phase 1
- Lead developer
- ImmunityBio
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
TriAd is a trivalent therapeutic cancer vaccine cocktail consisting of three distinct second-generation (E1-, E2b-deleted) adenovirus type 5 (Ad5) vectors, each encoding a different tumor-associated antigen: Carcinoembryonic Antigen (CEA; ETBX-011), Mucin 1 (MUC1; ETBX-051), and Brachyury (ETBX-061). Developed by ImmunityBio, the vaccine platform is designed to overcome pre-existing Ad5 immunity and induce robust Th1-mediated T-cell responses against multiple targets simultaneously. It is frequently evaluated in combination with other immunotherapies, such as the IL-15 superagonist N-803 (Anktiva) and the PD-L1/TGF-beta trap bintrafusp alfa (M7824), for the treatment of various solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, and chordoma.
- Other names
- TriAd vaccineAdenoviral vector vaccine TriAd
02
Targets
T (Brachyury transcription factor)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on TriAd.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TriAd.